Objectives:Oral contraceptive (OC) therapy has long been known to produce hypoandrogenemia. However, androgens are not part of any OC therapy available to women. This project was designed to evaluate the effects of low-estradiol containing OC, with or without methyltestosterone (MT), on cell proliferation and progesterone receptor (PgR) expression in mammary gland epithelia of virgin female rats.
Methods:Sixty rats were divided into four groups. One group received OCs, whereas a second group received OC plus MT. A third group of rats was treated with an antiandrogen to mimic the hypoandrogenemic effects caused by OC therapy. All treated groups were compared with age-matched untreated controls.
Results:After 15 weeks of treatment, no inflammatory, precancerous, or cancerous lesions were observed in any treatment group. OC plus MT therapy caused significant suppression of epithelial proliferation, a reduction in the number of proliferating cell nuclear antigen-labeled cells, and an increase in the number of PgR-labeled cells.
Conclusions:Our results suggest that a medication containing an estrogen-progestin-androgen combination has antiproliferative effects in mammary glands of experimental animals that could prove to have breast-protective potential in women.
1. Adams JB. Adrenal androgens and human breast cancer: A new appraisal. Breast Cancer Res Treat1998;51:183-188.
2.
2. Volm MD, Talamonti MS, Thangavelu M, Gradishar WK. Pituitary adenoma and bilateral male breast cancer: An unusual association. J Surg Oncol1997;64:74-78.
3.
3. Haraldsson K, Loman N, Zhang QX, Johannsson O, Olsson H, Borg A. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res1998;58:1367-1371.
4.
4. Hackenberg R, Schulz KD. Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. J Steroid Biochem Mol Biol1996;56:113-117.
5.
5. Carr BR, Bresau NA, Givens C, Byrd W, Barnett-Hamm C, Marshburn PB. Oral contraceptive pills, gonadotropin-releasing hormone antagonists, or use in combination for treatment of hirsutism: A clinical research center study. J Clin Endocrinol Metab1995;80:1169-1178.
6.
6. Luthold WW, Borges MF, Marcondes JAM, Hakohyama M, Wajchenberg BL, Kirschner MA. Serum testosterone fractions in women: Normal and abnormal clinical states. Metabolism1993;42:638-643.
7.
7. Coenen CMH, Thomas CMG, Borm GF, Hollanders JMG, Rolland R. Changes in androgens during treatment with four low-dose contraceptives. Contraception1996;53:171-176.
8.
8. Yamamoto T, Okada H. Clinical usefulness of low-dose oral contraceptives for the treatment of adolescent hyperandrogenemia. Asia Oceania J Obstet Gynaecol1994;20:225-230.
9.
9. Rosenfield RL, Lucky AW. Acne, hirsutism, and alopercia in adolescent girls. Clinical expressions of androgen excess. Endocrinol Metab Clin North Am1993;22:507-532.
10.
10. Moutos D, Smith S, Zacur H. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: A randomized trial. Contraception195;52:105-109.
11.
11. van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA, Thijssen JH. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception1990;41:345-352.
12.
12. Wiegratz I, Jung-Hoffmann C, Kuhl H. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception1995;51:341-346.
13.
13. Anderson FH, Francis RM, Peaston RT, Wastell HJ. Androgen supplementation in eugonadal men with osteoporosis: Effects of six months' treatment on markers of bone formation and resorption. J Bone Miner Res1997;12:472-478.
14.
14. Friedl KE, Hannan CJ Jr, Jones RE, Plymate SR. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism1990;39:69-74.
15.
15. Winneker RC, Wagner MM, Shaw CJ, Snyder BW. Antiandrogens do not reverse androgen-induced inhibition of sex hormone-binding globulin levels in adult female rhesus monkeys. Endocrinology1989;125:715-720.
16.
16. Jayo MJ, Register TC, Hughes CL, et al. Oral contraceptives and androgens: Effects on bone mass acquisition in female rats. J Bone Miner Res1999;14:S512-S512.
17.
17. Moore D. Rats. In: Rollin BE, Kesal ML, eds. The experimental animal in biomedical research, vol. II. Boca Raton, FL: CRC Press, 1996:251-277.
18.
18. Rodgers JB, Fauger MCM, Malluche H. Animal models for the study of bone loss after cessation of ovarian function. Bone1993;14:369-377.
19.
19. Mosekilde L. Assessing bone quality—animal models in preclinical osteoporosis research. Bone1995Suppl17:343S-352S.
20.
20. Swanson SM, Whitaker LM, Stockard CR, et al. Hormone levels and mammary epithelial and progesterone that mimics the preventative effect of pregnancy against mammary cancer. Anticancer Res1997;17:4639-4645.
21.
21. Hansson LL, Menander-Sellman K, Stenstrom A, Thorngren KG. Rate of normal longitudinal bone growth in the rat. Calif Tissue Res1972;10:238-251.
22.
22. Yamauchi H, Kushida K, Yamazaki K, Inoue T. Assessment of spine bone mineral density in ovariectomized rats using DEXA. J Bone Miner Res1995;10:1033-1039.
23.
23. Inoue T, Moriya A, Goto K, Tanaka T, Inazu M. What is the difference of bone growth in SHR and SD rats?Clin Exp Pharmacol Physiol1995Suppl1:S242-S243.
24.
24. Peterson CA, Eurell JAC, Erdman JW. Alterations in calcium intake on peak bone mass in the female rat. J Bone Miner Res1995;10:81-95.
25.
25. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat1998;48:221-229.
26.
26. Gasparini G, Meli S, Pozza F, Cazzavillan S, Bevilacqua P. PC-10 antibody to proliferating cell nuclear antigen (PCNA) is not related to prognosis in human breast carcinoma. Growth Regul1992;2:145-150.
27.
27. Imam SA, Young L, Chaiwun B, Taylor CR. Comparison of two microwave based antigen-retrieval solutions in unmasking epitopes in formalin-fixed tissue for immunostaining. Anticancer Res1995;15:1153-1158.
28.
28. Register TC, Jayo MJ, Jerome CP. Oral contraceptive treatment inhibits the normal acquisition of bone mineral in skeletally immature young adult female monkeys. Osteoporos Int1997;7:348-353.
29.
29. Manocharan K, Yang MG, Mickelsen O. Oral contraceptive steroids: Effects on various nutrient balances and body composition in adult female rats. Proc Soc Exp Biol Med1970;133:774-779.
30.
30. Liu FT, Lin HS. Effect of some contraceptive steroids on pituitary growth hormone content in female rats. Proc Soc Exp Biol Med1970;133:1354-1357.
31.
31. Slayden SM. Risks of menopausal androgen supplementation. Semin Reprod Endocrinol1998;16:145-152.
32.
32. Suzuki Y, Sinohara H. Plasma testosterone-binding proteins in the developing rat. Steroids1981;38:263-270.
33.
33. Noe G. Sex hormone binding globulin expression and colocalization with estrogen receptor in the human Fallopian tube. J Steroid Biochem Mol Biol199;68:111-117.
34.
34. Haerslev T, Jacobsen GK. Proliferating cell nuclear antigen in breast carcinomas. An immunohistochemical study with correlation to histopathological features and prognostic factors. Virchows Arch1994;424:39-46.
35.
35. Fanelli MA, Vargas-Roig LM, Gago FE, Tello O, Lucero De Angelis R, Ciocca DR. Estrogen receptors, progesterone receptors, and cell proliferation in human breast cancer. Breast Cancer Res Treat1996;37:217-228.
36.
36. Balleine RL, Earl MJ, Greenberg ML, Clarke CL. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer1999;79:1564-1571.
37.
37. Zhu X, Li H, Liu JP, Funder JW. Androgen stimulates mitogen-activated protein kinase in human breast cancer cells. Mol Cell Endocrinol1999;152:199-206.
38.
38. Lapointe J, Fournier A, Richard V, Labrie C. Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells. Endocrinology1999;140:416-421.
39.
39. Loos S, Schulz KD, Hackenberg R. Regulation of GCDFP-15 expression in human mammary cancer cells. Int J Mol Med1999;4:135-140.
40.
40. Formby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: Inverse effects on Bcl-2 and p53. Ann Clin Lab Sci1998;28:360-369.
41.
41. Haersley T, Skovgaard LT. Determining cell density in breast carcinomas. Hum Pathol1994;25:431-432.
42.
42. Pichon MF, Pallud C, BrunetM, Milgrom E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res1980;40:3357-3360.
43.
43. Balleine RL, Earl MJ, Greenberg ML, Clarke CL. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer1999;79:1564-1571.
44.
44. Xie B, Tsao SW, Wong YC. Induction of high incidence of mammary tumour in female Noble rats with a combination of 17beta-oestradiol and testosterone. Carcinogenesis1999;20:1069-1078.
45.
45. Furr BJA. The development of Casodex (bicalutamide); Preclinical studies. Eur Urol1996;29:83-95.
46.
46. Boyle GW, McKillop D, Phillips PJ, Harding JR, Pickford R, McCormick AD. Metabolism of Casodex in laboratory animals. Xenobiotica1993;23:781-798.
47.
47. Lebow MA. The pill and the press: Reporting risk. Obstet Gynecol1999;93:453-456.
48.
48. Hankinson SE, Colditz GA, Manson JE, et al. A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States). Cancer Causes Control1997;8:65-72.
49.
49. Ursin G, Wu AH, Hoover RN, et al. Breast cancer and oral contraceptive use in Asian-American women. Ajm J Epidemiol1999;150:561-567.
50.
50. Newcomb PA, Longnecker MP, Storer BE, et al. Recent oral contraceptive use and risk of breast cancer (United States). Cancer Causes Control1996;7:525-532.
51.
51. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA2000;283:485-491.
